Biomedal Life Science is devoted to the development and commercialization of products and services for life sciences research, and technology for industrial bioprocesses. Its own technology allowed the improvement of recombinant protein production.Biomedal Life Science also functions as a CRO (Contract Research Organization) and provides services and support to pharmaceutical or biotechnology companies.

Related News

CELL AND GENE THERAPY

VALNEVA AND IDT BIOLOGIKA ANNOUNCE COLLABORATION FOR PRODUCTION OF INACTIVATED COVID-19 VACCINE VLA2001

Valneva SE, IDT Biologika | November 30, 2021

news image

Valneva SE, a specialty vaccine company, and IDT Biologika announced their collaboration for the production of Valneva’s inactivated COVID-19 vaccine candidate VLA2001. This follows last week’s announcement that Valneva signed an Advance Purchase Agreement with the European Commission to supply up to 60 million doses of VLA2001, over two years. Under the collaboration, IDT Biologika will produce VLA2001’s drug substance at its Biosafety Level 3 facilities in Dess...

Read More

MEDICAL

PHAGENOVA BIO, INC. ANNOUNCES PUBLICATION DESCRIBING NEW METHOD FOR SAFE AND EFFECTIVE PULMONARY DELIVERY OF THERAPEUTICS

PhageNova Bio, Inc. | December 14, 2020

news image

PhageNova Bio, Inc. ("PhageNova") is pleased to declare the distribution of information created through a sponsored research agreement with Rutgers, The State University of New Jersey. The Med (a Cell Press distribution) article, entitled Targeted Phage Display-Based Pulmonary Vaccination in Mice and Non-human Primates, portrays another technique for protected and effective pulmonary delivery of therapeutics, including an aerosol vaccination strategy which is being developed to address...

Read More

CELL AND GENE THERAPY

ADICET BIO REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Adicet Bio, Inc. | September 06, 2022

news image

Adicet Bio, Inc. a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on August 31, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to five individuals hired by Adicet in August 2022. The employees received, in the aggregate, non-qualified stock options to purchase 114,200 shares of Adicet’s common stock with an exercise pric...

Read More

INDUSTRIAL IMPACT

RIVERSIDE PARTNERS' PORTFOLIO COMPANY SYNER-G ACQUIRES IMPACT

Riverside Partners | February 02, 2022

news image

Syner-G BioPharma Group a leading provider of Chemistry, Manufacturing, and Controls technical, regulatory, and compliance consulting services to pharmaceutical and biotechnology clients, today announced the acquisition of Impact Pharmaceutical Services. Based in Research Triangle Park, NC, IMPACT supports the outsourced medical writing, regulatory strategy, and regulatory publishing and submission needs of biotech and pharma companies from pre-IND through post-marketing of drugs and biologics. ...

Read More
news image

CELL AND GENE THERAPY

VALNEVA AND IDT BIOLOGIKA ANNOUNCE COLLABORATION FOR PRODUCTION OF INACTIVATED COVID-19 VACCINE VLA2001

Valneva SE, IDT Biologika | November 30, 2021

Valneva SE, a specialty vaccine company, and IDT Biologika announced their collaboration for the production of Valneva’s inactivated COVID-19 vaccine candidate VLA2001. This follows last week’s announcement that Valneva signed an Advance Purchase Agreement with the European Commission to supply up to 60 million doses of VLA2001, over two years. Under the collaboration, IDT Biologika will produce VLA2001’s drug substance at its Biosafety Level 3 facilities in Dess...

Read More
news image

MEDICAL

PHAGENOVA BIO, INC. ANNOUNCES PUBLICATION DESCRIBING NEW METHOD FOR SAFE AND EFFECTIVE PULMONARY DELIVERY OF THERAPEUTICS

PhageNova Bio, Inc. | December 14, 2020

PhageNova Bio, Inc. ("PhageNova") is pleased to declare the distribution of information created through a sponsored research agreement with Rutgers, The State University of New Jersey. The Med (a Cell Press distribution) article, entitled Targeted Phage Display-Based Pulmonary Vaccination in Mice and Non-human Primates, portrays another technique for protected and effective pulmonary delivery of therapeutics, including an aerosol vaccination strategy which is being developed to address...

Read More
news image

CELL AND GENE THERAPY

ADICET BIO REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Adicet Bio, Inc. | September 06, 2022

Adicet Bio, Inc. a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on August 31, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to five individuals hired by Adicet in August 2022. The employees received, in the aggregate, non-qualified stock options to purchase 114,200 shares of Adicet’s common stock with an exercise pric...

Read More
news image

INDUSTRIAL IMPACT

RIVERSIDE PARTNERS' PORTFOLIO COMPANY SYNER-G ACQUIRES IMPACT

Riverside Partners | February 02, 2022

Syner-G BioPharma Group a leading provider of Chemistry, Manufacturing, and Controls technical, regulatory, and compliance consulting services to pharmaceutical and biotechnology clients, today announced the acquisition of Impact Pharmaceutical Services. Based in Research Triangle Park, NC, IMPACT supports the outsourced medical writing, regulatory strategy, and regulatory publishing and submission needs of biotech and pharma companies from pre-IND through post-marketing of drugs and biologics. ...

Read More